142 related articles for article (PubMed ID: 27284428)
1. Indication of metronomic chemotherapy for metastatic breast cancer: Clinical outcomes and responsive subtypes.
Kontani K; Hashimoto SI; Murazawa C; Norimura S; Tanaka H; Ohtani M; Fujiwara-Honjo N; Date M; Teramoto K; Houchi H; Yokomise H
Mol Clin Oncol; 2016 Jun; 4(6):947-953. PubMed ID: 27284428
[TBL] [Abstract][Full Text] [Related]
2. Metronomic chemotherapy for metastatic breast cancer to prolong time to treatment failure to 12 months or more.
Kontani K; Hashimoto SI; Murazawa C; Norimura S; Tanaka H; Ohtani M; Fujiwara-Honjo N; Date M; Houchi H; Yokomise H
Mol Clin Oncol; 2013 Mar; 1(2):225-230. PubMed ID: 24649151
[TBL] [Abstract][Full Text] [Related]
3. Factors responsible for long-term survival in metastatic breast cancer.
Kontani K; Hashimoto S; Murazawa C; Norimura S; Tanaka H; Ohtani M; Fujiwara-Honjo N; Date M; Teramoto K; Houchi H; Yokomise H
World J Surg Oncol; 2014 Nov; 12():344. PubMed ID: 25395387
[TBL] [Abstract][Full Text] [Related]
4. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
[TBL] [Abstract][Full Text] [Related]
5. Whether low-dose metronomic oral cyclophosphamide improves the response to docetaxel in first-line treatment of non-triple-negative metastatic breast cancer.
Zhang J; Wang L; Wang Z; Wang B; Cao J; Lv F; Zhang S; Shao Z; Hu X
Oncotarget; 2017 Oct; 8(45):79527-79536. PubMed ID: 29108332
[TBL] [Abstract][Full Text] [Related]
6. The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease.
Kerbel RS; Shaked Y
Cancer Lett; 2017 Aug; 400():293-304. PubMed ID: 28202353
[TBL] [Abstract][Full Text] [Related]
7. Metronomic Chemotherapy for Primary Non-Metastatic Breast Cancer - a Systematic Review of the Literature.
Banys-Paluchowski M; Ruckhäberle E; Schütz F; Krawczyk N; Fehm T
Geburtshilfe Frauenheilkd; 2017 Feb; 77(2):142-148. PubMed ID: 28331236
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer.
Fedele P; Marino A; Orlando L; Schiavone P; Nacci A; Sponziello F; Rizzo P; Calvani N; Mazzoni E; Cinefra M; Cinieri S
Eur J Cancer; 2012 Jan; 48(1):24-9. PubMed ID: 21775129
[TBL] [Abstract][Full Text] [Related]
9. Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future?
Cazzaniga ME; Biganzoli L; Cortesi L; De Placido S; Donadio M; Fabi A; Ferro A; Generali D; Lorusso V; Milani A; Montagna E; Munzone E; Orlando L; Pizzuti L; Simoncini E; Zamagni C; Pappagallo GL;
Onco Targets Ther; 2019; 12():2989-2997. PubMed ID: 31114242
[TBL] [Abstract][Full Text] [Related]
10. Real-World Experience of Metronomic Chemotherapy in Metastatic Breast Cancer: Results of a Retrospective Unicenter Study.
Krajnak S; Krajnakova J; Anic K; Almstedt K; Heimes AS; Linz VC; Loewe A; Schmidt MW; Hasenburg A; Schmidt M; Battista MJ
Breast Care (Basel); 2023 May; 18(2):97-105. PubMed ID: 37261128
[TBL] [Abstract][Full Text] [Related]
11. Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity.
Montagna E; Cancello G; Bagnardi V; Pastrello D; Dellapasqua S; Perri G; Viale G; Veronesi P; Luini A; Intra M; Calleri A; Rampinelli C; Goldhirsch A; Bertolini F; Colleoni M
Clin Breast Cancer; 2012 Jun; 12(3):207-14. PubMed ID: 22520733
[TBL] [Abstract][Full Text] [Related]
12. Ixabepilone and Carboplatin for Hormone Receptor Positive/HER2-neu Negative and Triple Negative Metastatic Breast Cancer.
Osborne C; Challagalla JD; Eisenbeis CF; Holmes FA; Neubauer MA; Koutrelakos NW; Taboada CA; Vukelja SJ; Wilks ST; Allison MA; Reddy P; Sedlacek S; Wang Y; Asmar L; O'Shaughnessy J
Clin Breast Cancer; 2018 Feb; 18(1):e89-e95. PubMed ID: 28779904
[TBL] [Abstract][Full Text] [Related]
13. Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer.
Chen XL; Du F; Hong RX; Wang JY; Luo Y; Li Q; Fan Y; Xu BH
Chin J Cancer; 2016 Apr; 35():39. PubMed ID: 27112139
[TBL] [Abstract][Full Text] [Related]
14. Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer.
Yoshimoto M; Takao S; Hirata M; Okamoto Y; Yamashita S; Kawaguchi Y; Takami M; Furusawa H; Morita S; Abe C; Sakamoto J
Cancer Chemother Pharmacol; 2012 Aug; 70(2):331-8. PubMed ID: 22526409
[TBL] [Abstract][Full Text] [Related]
15. Metronomic oral chemotherapy with old agents in patients with heavily treated metastatic breast cancer.
Mutlu H; Musri FY; Artaç M; Kargi A; Özdogan M; Bozcuk H
J Cancer Res Ther; 2015; 11(2):287-90. PubMed ID: 26148586
[TBL] [Abstract][Full Text] [Related]
16. A Pilot Study of Extended Adjuvant Therapy with Metronomic Docetaxel for Patients with Operable Triple-Negative Breast Cancer.
Abdelmaksoud BA; Mohammed A; Toam MM
Asian Pac J Cancer Prev; 2020 Mar; 21(3):749-754. PubMed ID: 32212803
[TBL] [Abstract][Full Text] [Related]
17. Metronomic vinorelbine is an excellent and safe treatment for advanced breast cancer: a retrospective, observational study.
Liu CT; Hsieh MC; Su YL; Hung CM; Pei SN; Liao CK; Tsai YF; Liao HY; Liu WC; Chiu CC; Wu SC; Wang SH; Wei CT; Rau KM
J Cancer; 2021; 12(17):5355-5364. PubMed ID: 34335952
[TBL] [Abstract][Full Text] [Related]
18. Metronomic oral cyclophosphamide chemotherapy possibly contributes to stabilization of disease in patients with metastatic castration-resistant prostate cancer: a prospective analysis of consecutive cases.
Yashi M; Nishihara D; Mizuno T; Yuki H; Masuda A; Kambara T; Betsunoh H; Abe H; Fukabori Y; Muraishi O; Kamai T
Clin Genitourin Cancer; 2014 Oct; 12(5):e197-203. PubMed ID: 24674784
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Toxicity of Metronomic Chemotherapy in Metastatic Breast Cancer: Egyptian Experience.
Hussein MM; Gaafar RM; Abdel-Warith AM; Ahmed WA; Allahloubi NMA; Salem SE; Abdel-Salam IM
Clin Breast Cancer; 2017 Dec; 17(8):618-628. PubMed ID: 28625341
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response.
Wong NS; Buckman RA; Clemons M; Verma S; Dent S; Trudeau ME; Roche K; Ebos J; Kerbel R; Deboer GE; Sutherland DJ; Emmenegger U; Slingerland J; Gardner S; Pritchard KI
J Clin Oncol; 2010 Feb; 28(5):723-30. PubMed ID: 20026801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
